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Background: Gene therapy could provide an effective treatment of diabetes. Previous studies have investigated
the potential for several cell and tissue types to produce mature and active insulin. Gut K and L-cells could be
potential candidate hosts for gene therapy because of their special features.
Results: In this study, we isolated gut K and L-cells to compare the potential of both cell types to produce insulin
when exposed to similar conditions. The isolated pure K and L-cells were transfected with recombinant plasmids
encoding insulin and with specific promoters for K or L-cells. Insulin expression was studied in response to glucose
or meat hydrolysate. We found that glucose and meat hydrolysate efficiently induced insulin secretion from K and
L-cells. However, the effects of meat hydrolysate on insulin secretion were more potent in both cells compared
with glucose. Results of enzyme-linked immunosorbent assays showed that L-cells secreted more insulin compared
with K-cells regardless of the stimulator, although this difference was not statistically significant.
Conclusion: The responses of K and L-cells to stimulation with glucose or meat hydrolysate were generally
comparable. Therefore, both K and L-cells show similar potential to be used as surrogate cells for insulin gene
expression in vitro. The potential use of these cells for diabetic gene therapy warrants further investigation.
Keywords: Diabetes gene therapy, Insulin expression, K-cells, L-cellsBackground
Diabetes mellitus is a metabolic disorder associated with
abnormally high blood glucose levels in patients. Un-
treated or improperly treated diabetes can result in acute
complications that can lead to death or serious long-
term complications. Therefore, several approaches have
been considered to develop effective and convenient
treatments for diabetes, such as gene therapy [1-3]. In
the last decade, several gene therapy strategies have been
developed to regulate physiologic blood glucose levels in
patients with diabetes. One option that has been studied
is to replace pancreatic β-cells with engineered non-
pancreatic β-cells to generate potential target cells for
gene therapy. These surrogate β-cells were able to
synthesize and secrete active insulin; however, insulin se-
cretion was not regulated by glucose, unlike endogenous* Correspondence: zalinah@medic.upm.edu.my
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reproduction in any medium, provided the orβ-cells [4-7]. Recent studies using enteroendocrine cells
have shown the good potential for using these cells for
diabetes gene therapy. This is primarily because of their
ability to respond dynamically to a nutrient stimulus.
Enteroendocrine cells are located in the intestinal mu-
cosa and secrete incretin hormones such as glucose-
dependent insulinotropic peptide (GIP) and glucagon-
like peptide-1 (GLP-1). GIP and GLP-1 are naturally
secreted from gut K and L-cells, respectively. K-cells are
mainly scattered in the duodenum whereas L-cells are
predominantly found in the distal ileum. Both GIP and
GLP-1 are rapidly secreted following food intake and re-
turn to the basal level following their degradation into
inactive forms [8,9]. Many signaling factors including
nutrients, neural elements, and hormones are capable of
regulating the secretion of incretins although nutrients
in the lumen strongly stimulate GIP and GLP-1 secre-
tion [10,11]. It was reported that GIP and GLP-1 hor-
mones induce insulin secretion from pancreatic β-cells
to control blood glucose homeostasis. These two hor-
mones are also involved in many other metabolic path-
ways. For example, GIP promotes β-cell proliferation,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and induces gastric emptying and satiety [12].
Some properties of enteroendocrine cells make them
appealing candidates for surrogate β-cells [13]. First, K
and L-cells express prohormone convertases 2 and 3,
which are required to process proinsulin to mature insu-
lin [14]. Second, the expression of glucokinase and glu-
cose transporter II in K and L-cells provides a glucose
sensitive system similar to that of pancreatic β-cells [15].
Third, K and L-cells have cell-specific promoters like
GIP and GLP-1, respectively. Finally, K and L-cells are
easily accessible. Some research groups have studied in-
sulin expression under the control of a GIP promoter
and reported that K-cells secrete insulin in response to
different nutrient stimuli at different levels in vitro and
in vivo [16-18]. In other investigations, engineered L-cells
were used as the host cells for insulin expression and viral
promoters were used to express the insulin gene [19-21].
By contrast, the proglucagon promoter was used in
our previous study, in which we examined the expres-
sion of insulin in L-cells [22]. These observations
using K and L-cells raised a critical question concern-
ing which intestinal cells should be used in the con-
text of diabetes gene therapy for effective regulation
of glucose homeostasis.
Therefore, the aim of this study was to evaluate and
compare insulin expression efficiency in engineered K
and L-cells maintained in identical conditions. To
achieve this aim, pure K and L-cells were isolated from a
heterogeneous population of intestinal cells (STC-1 cells)
as basic models for gene expression studies. Then, we
examined insulin expression in response to stimulation by
glucose and meat hydrolysate (MH) in both cell types.
The results of the expression studies provide useful infor-
mation on the competency of both intestinal cell lines for
synthesizing and secreting insulin. We found that meat
hydrolysate is a potent stimulator of insulin expression in
both types. Interestingly, we found no significant differ-
ence in insulin expression between the two cell types.
Taken together, our results provide evidence to show that
gut K and L-cells can be used to study gene expression or
establish cell-based therapies. Our assessment of insulin
gene expression in these cells also indicates that K and
L-cells are potential candidate hosts for gene thera-
peutic treatment of diabetes or related disorders.Methods
Plasmid construction
GIP/Ins/pBud and GLP-1/Ins/pBud plasmids were
designed to establish insulin gene expression in K and
L-cells, respectively. The GIP promoter and the insulin
gene were inserted into the pBudCE4.1 vector (Invitrogen,
Carlsbad, CA, USA) for the construction of the GIP/Ins/pBud plasmid. The GLP-1 promoter and insulin gene
were used to construct the GLP-1/Ins/pBud plasmid. The
nucleotides of the GIP promoter region were amplified
from a rat-BAC clone (CH230-313 G4) obtained from the
BACPAC Resource Center (Children’s Hospital Oakland
Research Institute, Oakland, CA, USA). An upstream
sequence of ~1,100 bp of the rat GIP gene is essential for
promoter activity [23]. The nucleotides of proglucagon pro-
moter region (approximately 2,300 bp) were amplified from
the Glu.BS plasmid, which was kindly provided by Dr. Yvan
Gosmain (University of Geneva, Geneva, Switzerland) [24].
The human insulin gene (approximately 1,800 bp) was
amplified from human genomic DNA extracted from a
blood donor.
We also constructed GIP/Neo/pBlu and GLP-1/
Neo/pBlu plasmids, which were designed to isolate K
and L-cells, respectively, from a heterogeneous popu-
lation of intestinal cells. The GIP promoter and neomy-
cin resistant gene were cloned into the pBluescript-II-SK
vector (Stratagene, La Jolla, CA, USA) to construct the
GIP/Neo/pBlu plasmid. The GLP-1 promoter and neomy-
cin resistant gene were used to construct GLP-1/Neo/pBlu
plasmid. The neomycin resistant gene (1,200 bp) was
amplified from pcDNA3 plasmid (Invitrogen). A high fi-
delity PCR kit was used to amplify the PCR products. All
of the enzymes and kits used in this study were purchased
from Fermentas (Vilnius, Lithuania).Transfection and selection of stable K and L-cells
K and L-cells were isolated from STC-1 cell line,
which were kindly supplied by Prof. Douglas Hanahan
(University of California San Francisco, San Francisco,
CA, USA). The STC-1 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (fetal bovine serum) (PAA,
Pasching, Austria) at 37°C, as previously described
[22]. Cells were transfected using Lipofectamine-2000
(Invitrogen). To isolate pure K and L-cells, separate
batches of STC-1 cells were transfected with the GIP/
Neo/pBlu or GLP-1/Neo/pBlu plasmids. The trans-
fected cells were treated with an antibiotic (400 μg/ml
geneticin) for 2 weeks (Sigma, St Louis, MO, USA).
Five stable K-cell clones and five stable L-cell clones
treated with antibiotics were selected for propagation
as pure cell lines.
To study gene expression ability and efficiency in
these purified cells, we established insulin-producing
K and L-cells by transfecting the cells with the GIP/Ins/
pBud or GLP-1/Ins/pBud plasmids, respectively. The cells
were incubated in medium containing an antibiotic
(500 μg/ml zeocin) for 2 weeks. Five clones from each of
the transfected cell types that survived the zeocin condition
were selected for propagation and gene expression analyse.
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by an MTTassay, as previously described [22].
Assessment of insulin secretion
We assessed the capacity for insulin secretion essentially
as previously described [22]. All of the experimental
conditions and cell culture factors were identical for
both K and L-cells. Briefly, 3 × 106 cells were seeded in
six-well tissue culture plates. The cells were then incu-
bated in basal media containing DMEM, 5 mM glucose,
and 1% FBS overnight. The secretion test was started by
replacing the medium with fresh basal medium for 2 h.
Then, the cells were treated with (1) basal medium
(containing 5 mM glucose), (2) basal medium supple-
mented with 25 mM glucose (containing 25 mM glucose),
or (3) basal medium supplemented with 2% (w/v) meat
hydrolysate. The cells and media were collected 1 h later
to assess insulin gene expression.
Quantitative polymerase chain reaction (Q-PCR)
Q-PCR was performed to confirm that the K and L-cells
were efficiently isolated and to determine the insulin
mRNA expression level. Total RNA was extracted
from collected cells using an RNeasy plus mini kit
(Qiagen, Hilden, Germany). The cDNA was synthesized
by the iScript cDNA Synthesis Kit (Bio-Rad, Hercules,
CA, USA) and Q-PCR was performed using specific
primers. CFX Manager Software (version 1.0.1035.131;
Bio-Rad) and a Bio-Rad thermal cycler were used to
analyze the data. Gene expression was normalized for the
expression of mouse β-actin and β-2 microglobulin.
Enzyme-linked immunosorbent assay (ELISA)
A human insulin ELISA kit (ALPCO Diagnostics, Salem,
NH, USA) was used to measure the amount of insulin
that was secreted into the culture medium in each batch
of cells. This ELISA kit has 100% cross reactivity with
mature human insulin, whereas no reaction was reported
with other forms, such as pro-insulin, C-peptide. Samples
of cell culture medium for each treatment condition were
measured.
Statistical analysis
Statistical analyses were done using SPSS version 19 (SPSS
Inc., Chicago, IL, USA). Insulin levels and the percentage
increase in insulin secretion were treated as continuous
variables. The percentage increase in insulin secretion was
calculated as (post-induction insulin level – basal insulin
level) / basal insulin level × 100. Normality of distribution
was assumed based on observation of histograms and stat-
istical tests. Equality of variance was also checked. Paired
samples t-tests were used to compare the mean insulin
levels between basal and post induction. Independent
samples t-tests were used to compare the percentageincrease in insulin secretion between each cell type and
treatment. Confidence intervals and α were set at 95% and
0.05 respectively. For multivariate two-way analysis of
variance, both cell type and stimulant type were included
in the main effect models. There were no statistically sig-
nificant interaction terms. All model assumptions, includ-
ing normality, equal variance of residuals, model fitness,
linear relationships, and absence of statistical interaction
were tested and met.
Results and discussion
Isolation of stable intestinal K and L-cells
The STC-1 cell line is a heterogeneous population of in-
testinal cells that was first isolated and characterized by
Rindi et al. 1990. They reported that this cell line consists
of 7% K-cells, which express GIP, and 5% L-cells, which
express GLP-1 [25]. Therefore, STC-1 cells have been
used to isolate pure K and L-cells. In 2002, Ramshur et al.
used a selective method to isolate K-cells from STC-1 cells
[17]. Their method was designed to isolate pure cells from
the heterogeneous STC-1 cells by establishing resistance
to an antibiotic. To achieve this, an antibiotic resistance
gene is expressed under the control of a specific promoter
within the desired cells. The cells are then grown in a
medium containing the antibiotic. The cells that recognize
the promoter express the protein that confers antibiotic
resistance and only these cells are able to survive the
antibiotic treatment condition. We used the same method
to isolate K and L-cells in this study. The recombinant
GIP/Neo/pBlu plasmid, which includes a GIP promoter up-
stream of the neomycin resistant gene, was constructed to
isolate pure K-cells from STC-1 cells following treatment
with geneticin. The GIP promoter is specifically recognized
by K-cells. Therefore, the stable cells that survived the anti-
biotic condition were isolated as pure K-cells. The same
method was used to obtain pure L-cells [22].
To confirm that the isolated cells were indeed K and
L-cells, we performed Q-PCR to detect GIP and GLP-1
mRNAs. In this analysis, we compared mRNA expres-
sion levels in five isolated clones with those of STC-1
cells as a control. It was expected that the isolated cells
would show greater mRNA expression of GIP or GLP-1
than STC-1 cells because these incretins are specifically
expressed in K and L-cells, respectively, and not in other
intestinal cells, and because the STC-1 cell line contains
just 7% K-cells and 5% L-cells [25]. As expected, Q-PCR
showed that, in identical culture conditions, GIP mRNA
expression was greater in all five K-cell clones than in
the STC-1 cells (Figure 1A). However, GIP mRNA ex-
pression was not equal among the five clones. As shown
in Figure 1A, GIP mRNA expression was highest in clone 1
(K-1) and lowest in clone 5 (K-5) in the same experiment.
Similar results were observed for the isolated L-cell clones
Figure 1 Q-PCR analysis of the isolated clones. (A) GIP mRNA expression was higher in the five isolated K-cell clones than in STC-1 cells as a
control. (B) GLP-1 mRNA expressions was higher in the five isolated L-cell clones than in STC-1 cells as control. BioRad CFX Manager Software was
used to analyze expression data. Gene expression was normalized for mouse β-actin and β-2 microglobulin (β2m) mRNA expression. Error bars
indicate standard deviation.
Figure 2 Q-PCR analysis of insulin mRNA expression. Insulin expression in the five isolated K-cell clones (A) and the five isolated L-cell clones
(B) was measured following exposure to low (L, 5 mM) or high (H, 25 mM) glucose. L-S1–L-S5: clones 1–5 exposed to low glucose. H-S1–H-S5:
clones 1–5 exposed to high glucose. Gene expression was normalized for mouse β-actin and β-2 microglobulin (β2m) mRNA expression. Error
bars indicate standard deviation.
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Figure 3 Effects of glucose stimulation on insulin secretion from K and L-cells. Insulin secretion was measured in five K-cell clones (A) and
five L-cell clones (B) in response to low (basal, 5 mM) or high (final, 25 mM) glucose. Cell supernatants were collected and insulin was measured
by an ELISA. Insulin secretion increased in each of the isolated clones in response to high glucose. Error bars indicate standard deviation.
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GLP-1 mRNA expression compared with the other clones.
Several techniques have been developed to isolate a spe-
cific cell type from a heterogeneous population of cells.
Some methods exploit differences in the physical proper-
ties of cells, such as the size or density, to differentiate cell
types. For example, leukocytes and erythrocytes have dif-
ferent densities and can therefore be separated by density
gradient centrifugation. For cell types with a similar size
and density, flowcytometry is better able to separate each
cell type. In this technique, the cells are separated based
on their expression of one or more specific surface pro-
teins that specifically bind to corresponding monoclonal
antibodies [26]. Unfortunately, neither of these methods isFigure 4 Effects of meat hydrolysate stimulation on insulin secretion
cell clones (A) and five L-cell clones (B) in response to basal medium or m
insulin was measured by an ELISA. Insulin secretion increased in each of th
standard deviation.suitable for gut K and L-cells, as their size, density, and
surface proteins are similar to those of other intestinal
cells. Therefore, the antibiotic selection method is the
most reliable strategy to isolate these cells from the het-
erogeneous STC-1 cell population. Isolating a pure cell
line is vital to establish useful target cells for gene expres-
sion studies and compare transcription levels. Pure cell
lines are also essential for the study of post-translational
processing and protein modifications because pure cells
lack interference from surrounding cells.
In the present study, we repeated the Q-PCR assay for
isolated K and L-clones twice. The graph in Figure 1
shows that the mean mRNA expression for each clone
was not significantly different. All of the isolated clonesfrom K and L-cells. Insulin secretion was measured in five isolated K-
eat hydrolysate (MH) (2%, w/v). Cell supernatants were collected and
e isolated clones in response to meat hydrolysate. Error bars indicate
Table 1 Effects of high glucose and meat hydrolysate on mean insulin secretion in K and L-cells
Cell Stimulant n Mean(S.D) μIU/ml Mean diff. (CI95%) Mean% incr. (S.D) t-stat (dF) p-value *
K-cells Basal 20 1.22 (0.44) −1.50 144 (96) −9.96 (19) <0.001
High glucose 20 2.72 (0.75) (−1.81,-1.18)
Basal 20 1.20 (0.45) −3.18 312 (172) −20.88 (19) <0.001
High MH 20 4.39 (1.21) (−3.50, -2.86)
L-cells Basal 20 1.00 (0.58) −3.43 776 (1250) −21.31 (19) <0.001
High Glucose 20 4.43 (0.60 (−3.77,-3.09)
Basal 20 1.02 −3.41 410 (271) −10.40 (19) <0.001
High MH 20 4.42 (−4.09,-2.72)
*paired t-test (p-value <0.05 is significant).
Ahmad et al. BMC Biotechnology 2012, 12:64 Page 6 of 9
http://www.biomedcentral.com/1472-6750/12/64expressed the specific RNA (i.e., GIP in K-cells and
GLP-1 in L-cells) at a greater level than did STC-1 cells.
Based on these results, we selected and propagated the
K-1 and L-2 clones because their mRNA expression
levels of GIP and GLP-1, respectively, were greater than
those of the other clones.
Isolation of insulin-producing K and L-cells
Insulin-producing K-cells were established by transfect-
ing the isolated K-1 clone with the GIP/Ins/pBud plas-
mid. This plasmid includes an insulin gene under the
control of a GIP promoter. This plasmid contained the
zeocin resistant gene to select stably transfected cells fol-
lowing treatment with zeocin. The same approaches
were used to develop insulin-producing L-cells [22]. The
zeocin-resistant clones were isolated and used in insulin
expression studies. Insulin expression was determined
by Q-PCR assay to measure mRNA expression and by
ELISA to measure protein expression. The results of
these analyses showed that both cell lines are capable of
producing active insulin. By comparing insulin gene ex-
pression under the control of different promoters in
each cell type also allowed us to determine which of
these enteroendocrine cell types is more efficient and
suitable for use as host cells for diabetes gene therapy.
Insulin secretion from K and L-cells in response to
glucose and meat hydrolysate
The ability of the GIP and GLP-1 promoters to regulate
insulin gene transcription was determined by Q-PCR.Table 2 Comparison of the effects of glucose and meat hydro
K and L-cells
Cell type Stimulant n Mean% i
K-cells Glucose 20 14
MH 20 31
L-cells Glucose 20 22
MH 20 41
*independent t-test (p-value <0.05 is significant).The five insulin-producing K and L-cell clones were
exposed to low or high glucose concentrations. Total
RNA were extracted from the cells following treatment
for Q-PCR analysis. Consistent with the results of previ-
ous studies that compared GIP or GLP-1 promoter ac-
tivities [17,18,22], we found no differences in human
insulin mRNA expression between the high and low glu-
cose conditions (Figure 2). These results indicate that in-
sulin gene transcription under the control of the GIP
and GLP-1 promoters is independent of changes in glu-
cose concentration in the culture medium, and that an
increase in glucose concentration does not significantly
influence promoter activity in vitro. The reasons behind
it are still unclear but it seems that the responsiveness of
the K and L-cells to glucose concentration change is
probably due to the glucose detector system in these
cells, not because of the transcriptional regulation path-
ways at the RNA level. Although the activities of the
GIP and GLP-1 promoters were not responsive to the
change in glucose concentrations, we used these promo-
ters to construct plasmids expressing the insulin gene.
The specificity of the GIP and GLP-1 promoters allows se-
lective expression of the insulin gene in the K and L-cells,
respectively.
The insulin protein secretion in response to the glu-
cose induction was studied in insulin producing K and
L-cells by ELISA test. The results of the ELISAs showed
that increasing the glucose concentration from 5 mM to
25 mM increased insulin secretion in all insulin-
producing K and L-cells (Figure 3). As shown inlysate on the percentage increase in insulin secretion in
ncrease (S.D) Mean diff. (CI95%) p-value *
4 (95) −168 (−258,-78) 0.001
2 (172)
2 (232) −188 (−349,-26) 0.024
0 (271)
Table 3 Comparison of the percentage increase in insulin secretion between K and L-cells treated with high glucose or
meat hydrolysate
Stimulant Cell type n Mean% increase (S.D) Mean diff. (CI95%) p-value *
High Glucose K-cells 20 144 (95) −78 (−194,32) 0.176
L-cells 20 222 (232)
MH K-cells 20 313 (172) −98 (−244,48) 0.182
L-cells 20 410 (271)
*independent t-test (p-value <0.05 is significant).
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(Ins.K-3) were increased by about 2.4 fold, reaching 3.29
μIU/ml and 3.49 μIU/ml, respectively. Meanwhile, insu-
lin secretion in L-cells increased by 2.7 fold after glucose
induction (Figure 3B) [22]. We also examined insulin se-
cretion in response to 2% meat hydroslyate (Figure 4),
which contains a mixture of free amino acids and pep-
tides. Exposure to meat hydrolysate increased insulin se-
cretion by 4.6 fold in L-cell clone 2 (Ins.L-2) and by 3.7
fold in K-cell clone 3 (Ins.K-3). Therefore, exposure to
meat hydrolysate markedly increased insulin secretion in
both cell types, consistent with the results of earlier stud-
ies [16,17,20].
Reviewing Q-PCR and ELISA data, it seems that insu-
lin expression in K and L-cells is regulated by glucose
regulated at the protein level but not at the mRNA level.
The findings may explain the inability of the GIP and
GLP-1 promoters to sense changes in glucose levels. In-
stead, the intestinal K and L-cells may sense changes in
glucose level through existing glucose-sensitive path-
ways, such as glucokinase and glucose transporter II,
which ultimately promote insulin secretion into the
medium but not gene expression. Nevertheless, our
results confirmed that the engineered gut K and L-cells
could secrete insulin in response to stimulation with glu-
cose or meat hydrolysate.
Comparison of the insulin-producing ability of K and
L-cells
Insulin secretion from K and L-cells was markedly
increased by exposure to high glucose (25 mM) or meat
hydrolysate compared with the basal state (5 mM glucose).
Comparison of basal and stimulated insulin secretion
between the two cells was statistically significant for
both glucose and meat hydrolysate (p< 0.001). As shown
in Table 1, exposure to high glucose or meat hydrolysateTable 4 Multivariate analysis of the percentage increase in in
Cell type n aAdjusted mean Of% insulin increase (CI95%) * bAdju
K-cells 40 228 (165,292)
L-cells 40 316 (253,380)
The final model included cell type and stimulant type as independent factors (p < 0
*Adjusted mean (two-way ANOVA controlling for type of stimulant).
†With Bonferroni adjustment of the 95% CI.significantly increased insulin secretion from K-cells, as
compared with the basal levels. High glucose and meat
hydrolysate had similar effects on insulin secretion in
L-cells. These results indicate that the K and L-cells
have a functional nutrient sensing system that can re-
spond to different nutrients.
We next compared the effects of glucose and meat hy-
drolysate on the percentage increase in insulin secretion
relative to basal levels in both cell types. As shown in
Table 2, the percentage increase in insulin secretion was
significantly greater following exposure to meat hydrolysate
than high glucose in both K-cells (p = 0.001) and L-cells
(p= 0.024). We suspect that meat hydrolysate has a greater
stimulatory effect than glucose on insulin secretion be-
cause it consists of multiple amino acids and fatty acids,
which may have greater stimulatory factors compared
with glucose. Notably, it has been reported that fat,
carbohydrate, protein, and mixed amino acids can
stimulate GLP-1 secretion from L-cells and GIP secretion
from K-cells [27,28].
We then sought to determine which cell line shows
the best responses to each stimulus and hence provide
the more suitable host for gene therapy. Accordingly, we
compared the percentage increase in insulin secretion
between K-cells and L-cells. Interestingly, these compari-
sons revealed no significant differences in the responses
of K and L-cells to high glucose (p = 0.176) or meat hy-
drolysate (p = 0.182) (Table 3).
Finally, we conducted multivariate analysis with the
percentage increase in insulin secretion as the dependent
variable. The final model included both cell type and
stimulant type, which together explained about 18%
(R2 = 0.18) of the variation in the percentage increase in
insulin secretion (Table 4). After controlling for stimu-
lus, the percentage increase in insulin secretion was
slightly higher in L-cells than in K-cells (316% vs. 228%),sulin secretion
sted mean diff. Of% insulin increase (CI95%) † F-stat(dF) p-value
−87 (−178,2) 3.8 (1,77) 0.056
.05; R2 = 0.18).
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Since the p-value was very close to the pre-specified α
(0.05), it is possible the sample size was too small to de-
tect this difference. It is reasonable to expect that the
responses of K and L-cells to specific nutrient and its
levels are not equal. It is possible that in physiological
conditions, other elements or factors that are otherwise
absent in cell culture conditions might influence insulin
secretion.
Conclusion
In conclusion, nutrients are an important signal that can
stimulate both K and L-cells through direct contact with
these cells. K and L-cells show different responses to dif-
ferent nutrients, although their responses were greater
to meat hydrolysate than to glucose. Nevertheless, the
relative insulin secretion from K and L-cells in response
to both stimuli was not markedly different. These results
provide compelling evidence supporting the use of both
cell types as suitable candidates for diabetes gene ther-
apy and warrant further studies to examine their clinical
applications. To avoid erroneous conclusions, the same
results should be reproduced in vivo, as many therapies
that are effective in vitro are ineffective in vivo for a var-
iety of reasons. The main limitations of in vitro studies
include the proposed delivery system and toxicity against
the host, which was not evident in vitro. Future studies
should provide more insight into the potential use of
both cells for in vivo gene therapy or as ex vivo insulin
secreting cells for use as an ectopic transplant. Studies
are also necessary to confirm that our exciting results
can be repeated in animal models. It is also important to
identify factors (e.g., neural elements and hormones)
that may interfere with insulin gene expression in
physiological conditions when using these cell lines.
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